Objective
=========

We characterized the ability of mometasone furoate/formoterol (MF/F) combination to improve asthma control in adults/adolescents inadequately controlled on low-, medium-, and high-dose inhaled corticosteroids (ICS).

Methods
=======

Changes from baseline to endpoint (last evaluable visit) in Asthma Control Questionnaire (ACQ) scores were assessed in subjects from 3 Phase III trials (low- \[n=746\], medium- \[n=781\], and high-dose \[n=728\] previous ICS use). The ACQ categorizes asthma symptoms and use of rescue-medication using a 7-point scale (0=totally controlled, 6=severely uncontrolled). In two placebo controlled trials, subjects were randomized to receive MF/F (100/10μg or 200/10μg), MF (100μg or 200μg), F (10μg), or placebo (26 weeks; all twice-daily \[BID\] via metered-dose inhaler \[MDI\]); In a non-placebo controlled trial, subjects were randomized to receive MF/F 200/10μg, MF/F 400/10μg, or MF 400μg (12 weeks; all BID via MDI).

Results
=======

Baseline ACQ scores (1.23--1.38 (MF/F 100/10μg study), 1.41--1.47 (MF/F 200/10μg study), and 1.83--1.87 (MF/F 200/10 and 400/10μg study) indicated that subjects in all trials were not well controlled (\<0.75) on ICS monotherapy. MF/F yielded ACQ improvements (100/10μg=--0.36; 200/10μg=--0.40) vs MF (100μg=--0.26; 200μg=--0.23), and deteriorations with F 10μg (+0.07; +0.11) and placebo (+0.24; +0.14). MF/F 400/10μg improved asthma control by --0.51 compared with --0.33 for MF 400μg monotherapy. Improvements for MF/F at all doses achieved minimal importance difference of ≥0.5 point increase.

Conclusion
==========

MF/F showed clinically important improvement in asthma control at all strengths and was better than MF, F and placebo.
